Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Treatment of Male Androgenetic Alopecia
Description
The presentation discusses the treatment options for male androgenetic alopecia, starting with the importance of thorough clinical evaluation, including documenting hair loss and using the Norwood classification system. Various treatment strategies are outlined based on the severity of the condition, including topical and oral minoxidil, finasteride, and platelet-rich plasma (PRP) therapy. The speaker emphasizes the rising popularity of oral minoxidil due to its convenience. Comparisons are made between oral and topical forms of medication, with insights into effectiveness and safety profiles. Notably, topical finasteride is shown to be effective similar to oral finasteride, leading to discussions on combination therapies. The presentation critically addresses potential side effects associated with medications and the concept of post-finasteride syndrome, highlighting the importance of informed patient choices. Other treatments mentioned include exosomes, mesotherapy, and newer options like lasers and botulinum toxin, although results vary greatly. While ongoing studies for various treatments are acknowledged, some approaches—such as dutasteride mesotherapy—did not show promising results, underscoring the need for further research. Overall, the speaker provides a comprehensive overview of current and emerging treatments for androgenetic alopecia, combining clinical insights with patient management considerations.
View moreConclusions
- Gradually progressive thinning is a common symptom of male androgenetic alopecia, as seen in patients ranging from adolescents to adults.
- Various treatment options exist for androgenetic alopecia, including oral and topical finasteride and minoxidil.
- Low-dose oral minoxidil has been effectively used for both male and female pattern hair loss, showing considerable benefits.
- Oral minoxidil offers advantages in convenience and reduced local irritation compared to topical forms.
- In cases of non-improvement with initial treatments, platelet-rich plasma (PRP) therapy may be considered, although variable results have been observed.
- Topical finasteride has shown efficacy similar to oral finasteride, providing a viable alternative for patients wary of systemic side effects.
- Clinical evidence suggests safety concerns, though adverse effects from treatments like minoxidil can be managed effectively in most patients.
- Platelet-rich plasma treatment can increase hair density, but it may show results comparable to placebo in some cases.
- Emerging treatments, such as exosomes, botulinum toxin, clascoterone, and pyrilutamide are under investigation, showing promise for future applications in hair restoration.
- Rodney D. Sinclair, et al. 2019. Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. J Am Acad Dermatol;81(2):648-649. doi: 10.1016/j.jaad.2019.04.054.
- Cheok, A. 2020. Evaluation of platelet-rich plasma as a treatment for androgenetic alopecia: A randomized controlled trial. J Am Acad Dermatol;83:1298-303.
- Saceda-Corralo, D. et al. 2017. Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia. Int J Trichology; 9(3): 143-145. doi: 10.4103/ijt.ijt 73 16.
- Saceda-Corralo, D. et al. 2022. Mesotherapy With Dutasteride for Androgenetic Alopecia: A Retrospective Study in Real Clinical Practice. J Drugs Dermatol;21(7):742-747. doi: 10.36849/JDD.6610.
- Aditya K Gupta, et al. 2020. Systematic review of exosome treatment in hair restoration: Preliminary evidence, safety, and future directions.
- Park B-S, et al. 2022. Effects of exosome from adipose-derived stem cell on hair loss: A retrospective analysis of 39 patients. J Cosmet Dermatol;21:2282-2284.
- Sehdev, S., Neema, S., and Vasudevan, B. 2017. A Pilot Study to Evaluate Effectiveness of Botulinum Toxin in Treatment of Androgenetic Alopecia in Males. J Cutan Aesthet Surg;10(3):163-167. PMCID: PMC5782443 doi: 10.4103/JCAS.JCAS 77 17.